1. 096 Assessment of the efficacy of erenumab during the open-label treatment (13–24 weeks) of subjects with episodic migraine who failed 2–4 prior preventive treatments: results of the LIBERTY study. (29th July 2019) Authors: Giles, Lauren; Reuter, Uwe; Goadsby, Peter; Lanteri-Minet, Michel; Hours-Zesiger, Peggy; Fernandes, Chrystel; Ferrari, Michel; Klatt, Jan Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 90(2019)e7 Page Start: A31 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Long-term Efficacy and Safety of Erenumab: Results From 64 Weeks of the LIBERTY Study. (1st June 2021) Authors: Goadsby, Peter J.; Reuter, Uwe; Lanteri-Minet, Michel; Paiva da Silva Lima, Gabriel; Hours-Zesiger, Peggy; Fernandes, Chrystel; Wen, Shihua; Tenenbaum, Nadia; Kataria, Aditi; Ferrari, Michel D.; Klatt, Jan Journal: Neurology Issue: Volume 96:Number 22(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗